Transoral Surgery

PROCEDURE3 trials

Sponsors

UNC Lineberger Comprehensive Cancer Center, ECOG-ACRIN Cancer Research Group, Rutgers, The State University of New Jersey

Conditions

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Head and Neck CancerHuman Papilloma Virus InfectionOropharyngeal Human Papillomavirus-Positive Squamous Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckStage III Squamous Cell Carcinoma of the Oropharynx

Phase 2

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

CompletedNCT01612351

UNC Lineberger Comprehensive Cancer CenterHead and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck

Start: 2012-06-01End: 2025-05-19Updated: 2026-03-17

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

Active, not recruitingNCT01898494

ECOG-ACRIN Cancer Research GroupHuman Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx +1

Start: 2014-01-22End: 2026-12-01Updated: 2026-04-01

Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy

Active, not recruitingNCT04920344

Rutgers, The State University of New JerseyClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 +1

Start: 2021-05-19End: 2026-09-01Updated: 2026-08-14

Related Papers

Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.

Journal of Clinical Oncology2024-06-017 citations

Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.

Journal of Clinical Oncology2023-06-011 citations

Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.

Journal of Clinical Oncology2022-06-0110 citations

Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).

Journal of Clinical Oncology2020-05-2097 citations

Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial.

2020-02-1447 citations

Multimodality risk adapted therapy with induction carboplatin/paclitaxel/lapatinib for SCCHN amenable to transoral surgery.

Journal of Clinical Oncology2017-05-20

E3311 trial of transoral surgery for oropharynx cancer: Implementation of a novel surgeon credentialing and quality assurance process.

Journal of Clinical Oncology2016-05-2010 citations